GDP regimen as salvage treatment for relapsed refractory non-Hodgkin's lymphoma
10.3760/cma.j.issn.1009-9921.2012.08.007
- VernacularTitle:GDP方案挽救治疗复发难治性非霍奇金淋巴瘤的临床研究
- Author:
Jin ZHAO
;
Kaichao FENG
;
Zhiqiang ZHAO
;
Liping SU
;
Jun WANG
;
Li MA
;
Jianxia HE
;
Lieyang WANG
;
Xi LI
;
Yanli WANG
;
Weier HAN
;
Yuping ZHENG
- Publication Type:Journal Article
- Keywords:
Lymphoma,non-Hodgkin;
Antineoplastic combined chemotherapy protocols;
Recurrence;
Refractory
- From:
Journal of Leukemia & Lymphoma
2012;21(8):472-474
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effect and safety of GDP regimens (gemcitabine,cisplatin,dexamethasone) as salvage chemotherapy in relapsed refractory non-Hodgkin’s lymphoma (NHL).Methods Clinical response and adverse effects of 34 NHL patients treated by GDP regimens were analyzed retrospectively.Results The overall response rate (ORR) was 52.9 ％ (18/34),there was no statistic difference between ORR in relapsed NHL [72.7 ％ (8/11)] and that in refractory ones [43.5 ％ (10/23)](P =0.11).The ORR for B-NHL was 64.0 ％ (16/25),while for T-NHL was 22.2 ％ (2/9),there was no statistic difference between them (P =0.052).The ORR for low risks groups was 66.7 ％ (6/9),while it for intermediate-risk and high-risk ones were 55.6 ％ (10/18) and 28.6 ％ (2/7),respectively,the effect of GDP regimens for low-risk group was better for high-risk ones,but there was no statistic difference (P =0.349).The incedience of Ⅲ-Ⅳ granulopenia reduced was 23.5 ％ (8/34) and there were no Ⅲ-Ⅳ gastrointestinal adverse reactions or liver and kidney toxicity.Conclusion GDP regimens were efficient and less toxic as second-line salvage chemotherapy.
